Author

G. Pruneri

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 7 Immunology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Organism:human· 8 Approach:experimental assay· 6 Assay:bulk RNA-seq· 5 Research Focus:cell type annotation· 5 Approach:statistical model· 5 Research Focus:cancer & tumor microenvironment· 4 Research Focus:gene regulatory network inference· 4 Research Focus:differential expression· 3

Frequent Co-Authors

L. Magnani· 5 shared A. Belfiore· 2 shared A. Vingiani· 2 shared B. Gyorffy· 2 shared C. Coombes· 2 shared C. Davies· 2 shared D. Patten· 2 shared G. Corleone· 2 shared

Activity by Year

2017-2022 · peak 3/yr

Co-Author Collaboration Network

10 top collaborators · 25 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

5 shared papersCancer Biology

L. Magnani

Mutual co-authors in cluster

Author profile →

8 papers

Recent·Most cited

Landscape of immune-related signatures induced by targeting of different epigenetic regulators in melanoma: implications for immunotherapy

A. Anichini, A. Molla, G. Nicolini, V. E. Perotti, F. Sgambelluri, A. Covre, C. Fazio, M. F. Lofiego, A. M. Di Giacomo, S. Coral, A. Manca, M. C. Sini, M. Pisano, T. Noviello, F. Caruso, , R. Mortarini

This paper identifies immune-related gene signatures induced by four epigenetic inhibitors in melanoma cells, finding that guadecitabine most strongly upregulates immune-related genes and activates innate immunity pathways.

bioRxiv · Apr 13, 2022Immunology

Genetic and epigenetic driven variation in regulatory regions activitycontribute to adaptation and evolution under endocrine treatment

N. Slaven, R. Lopes, E. Canale, D. Ivanoiu, C. Pacini, I. A. Monteiro Barbosa, M. Bleu, S. Bravaccini, S. Ravaioli, M. V. Dieci, G. Pruneri, G. Galli, I. Barozzi, L. Magnani

This study identifies non-coding DNA alterations in hormone-dependent breast cancer that contribute to endocrine therapy resistance and disease progression.

bioRxiv · Feb 15, 2022 · PreprintCancer Biology

Decellularized Normal and Tumor Extracellular Matrix as Scaffold for Cancer Organoid Cultures of Colorectal Peritoneal Metastases

L. Varinelli, M. Guaglio, S. Brich, S. Zanutto, A. Belfiore, F. Zanardi, F. Iannelli, A. Oldani, E. Costa, M. Chighizola, S. P. Minardi, S. Fortuzzi, M. Filugelli, G. Garzone, F. Pisati, , M. Gariboldi

The paper develops 3D organoid cultures using decellularized ECM from colorectal peritoneal metastases to model the metastatic niche and assess chemotherapy response.

bioRxiv · Jul 15, 2021 · PreprintCancer Biology

VGLL1 drives therapy resistance in estrogen receptor positive breast cancer

C. Gemma, C. Lai, A. Singh, A. Belfiore, N. Portman, H. Z. Milioli, M. Periyasamy, S. Abuelmaaty, A. J. Nicholls, C. Davies, N. R. Patel, G. Simmons, H. Fan, V. Nguyen, L. Magnani, , S. Ali

This study identifies VGLL1 as a driver of resistance to endocrine therapy in ER+ breast cancer and shows that targeting VGLL1/TEAD interaction can inhibit resistant cell growth.

bioRxiv · Nov 29, 2020Cancer Biology

Single-cell Transcriptomics reveals multi-step adaptations to endocrine therapy

S. P. Hong, T. E. Chan, Y. Lombardo, G. Corleone, N. Rotmensz, G. Pruneri, K. R. McEwen, C. R. Coombes, I. Barozzi, L. Magnani

This study uses single-cell transcriptomics to identify pre-adapted cells that undergo reprogramming to develop resistance to endocrine therapy in breast cancer.

bioRxiv · Dec 2, 2018Cancer Biology

A cell-of-origin epigenetic tracer reveals clinically distinct subtypes of high grade serous ovarian cancer

P. Lo Riso, C. E. Villa, G. Gasparoni, R. Luongo, A. Manfredi, A. Vingiani, A. Jungmann, A. Garbi, M. Lupia, P. Laise, V. Das, G. Pruneri, G. Viale, N. Colombo, U. Cavallaro, , G. Testa

This study identifies DNA methylation differences between fimbrial and ovarian surface epithelia to create an epigenetic tracer that stratifies high grade serous ovarian cancer into clinically distinct subtypes with prognostic significance.

bioRxiv · Nov 30, 2018Cancer Biology

SREBP1 drives KRT80-dependent cytoskeletal changes and invasive behavior in endocrine resistant ERα breast cancer

L. Magnani, Y. Perone, A. Farrugia, A. Meira, B. Gyorffy, C. Ion, A. Uggetti, D. Patten, A. Chronopoulos, M. Faronato, S. Shousha, J. Steel, C. Davies, N. Patel, A. del Rio Hernandez, , F. Calvo

This study identifies SREBP1-driven KRT80 upregulation as a mechanism promoting invasion in endocrine-resistant ERα breast cancer through cytoskeletal changes and increased tumor stiffness.

bioRxiv · Jul 30, 2018Cancer Biology

Enhancers mapping uncovers phenotypic heterogeneity and evolution in patients with luminal breast cancer.

D. Patten, G. Corleone, B. Gyorffy, E. Erdos, A. Saiakhova, K. Goddard, A. Vingiani, S. Shousha, L. S. Pongor, D. Hadjiminas, G. Schiavon, P. Barry, C. Palmieri, C. Coombes, P. Scacheri, , L. Magnani

This study maps enhancers in luminal breast cancer to reveal phenotypic heterogeneity and its evolutionary dynamics during treatment.

bioRxiv · Sep 26, 2017Cancer Biology